{
  "entity_id": "B-002550",
  "folder": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
  "name": "Australian Bleeding Disorders Registry Steering Committee",
  "type": "Advisory Body",
  "jurisdiction": "Commonwealth",
  "portfolio": "Health, Disability and Ageing",
  "website": "https://www.blood.gov.au/governance-and-committees",
  "data_status": "inherited",
  "completeness": {
    "has_strategy_brief": true,
    "has_strategy_structured": true,
    "has_vision": true,
    "has_kpi_targets": true,
    "has_kpi_results": true,
    "has_strategy_overview": true,
    "has_legislation_text": true,
    "has_legislation_structured": false,
    "has_global_initiatives_text": false,
    "has_global_initiatives_structured": false,
    "n_global_initiatives": 0,
    "has_ideas": true,
    "has_artifacts": true,
    "n_ideas": 12,
    "n_legislation": 0,
    "n_artifacts": 3,
    "n_kpi_targets": 3,
    "n_kpi_results": 3,
    "n_outcomes": 1,
    "verified_own_data": false,
    "vision_shared_with_n_others": 2
  },
  "strategy_profile": {
    "status": "needs_review",
    "confidence": "low",
    "summary": "The primary policy objectives of the National Blood Agreement signed by the Commonwealth, state and territory governments are:\n\nS to provide an adequate, safe, secure and affordable supply of blood products, blood related products and blood related services\nS to promote the safe and high-quality management and use of blood products, blood related products and blood related services in Australia. [CP p.10]",
    "official_site_url": "https://www.blood.gov.au/governance-and-committees",
    "source_documents": [
      {
        "type": "annual_report",
        "title": "NBA Annual Report 2024-25",
        "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf",
        "period": "2024-25",
        "confidence": "high"
      },
      {
        "type": "annual_report",
        "title": "NBA Annual Report 2023–24 (WCAG accessible)",
        "url": "https://www.blood.gov.au/sites/default/files/documents/2024-10/NBA0912%20%E2%80%93%20NBA%20Annual%20Report%202023%E2%80%9324%20WCAG%20accessible.pdf",
        "period": "2023-24",
        "confidence": "high"
      },
      {
        "type": "corporate_plan",
        "title": "NBA Corporate Plan 2025-26",
        "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf",
        "period": "2025-26",
        "confidence": "high"
      }
    ],
    "purpose": {
      "text": "The primary policy objectives of the National Blood Agreement signed by the Commonwealth, state and territory governments are:\n\nS to provide an adequate, safe, secure and affordable supply of blood products, blood related products and blood related services\nS to promote the safe and high-quality management and use of blood products, blood related products and blood related services in Australia. [CP p.10]",
      "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf",
      "source_page": 10,
      "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=10"
    },
    "vision": {
      "text": "To save and improve Australian lives and patient outcomes through a world-class blood supply. [AR p.16]",
      "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf",
      "source_page": 16,
      "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=16"
    },
    "strategic_priorities": [],
    "values": [
      {
        "name": "APS Values",
        "description": "",
        "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf",
        "source_page": null
      }
    ],
    "outcomes": [
      {
        "name": "Access to a secure supply of safe and affordable blood products",
        "description": "Access to a secure supply of safe and affordable blood products, including through national supply arrangements and coordination of best-practice standards within agreed funding policies under the national blood arrangements. [AR p.16]",
        "activities": [
          "works with all Australian governments to determine the clinical requirements for blood and blood-related products",
          "negotiates and manages national contracts with suppliers of blood and blood products",
          "assesses risks to the blood supply and develops contingency plans",
          "supports the work of all Australian governments to improve the way blood products are governed, managed and used"
        ],
        "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf",
        "source_page": 16,
        "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=16"
      }
    ],
    "performance_measures": [
      {
        "code": "NSP&B",
        "measure": "National Supply Plan and Budget",
        "target": "<5% variation",
        "latest_result": "Actual results were 4.3% ($79.4 million) below the National Supply Plan and Budget.",
        "status": "Not achieved",
        "target_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf",
        "target_source_page": 34,
        "result_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf",
        "result_source_page": 42
      },
      {
        "code": "Ig",
        "measure": "Appropriate access and use of immunoglobulin",
        "target": "<8% growth in Ig demand under approved criteria",
        "latest_result": "The rate of growth of immunoglobulin (Ig) use was 6.7%.",
        "status": "Substantially achieved",
        "target_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf",
        "target_source_page": 34,
        "result_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf",
        "result_source_page": 42
      },
      {
        "code": "NBA",
        "measure": "National performance reporting and benchmarking",
        "target": "Published performance reporting and benchmarking information on the NBA website for the blood sector community",
        "latest_result": "Published performance reporting and benchmarking information on the NBA website for the blood sector community.",
        "status": "Achieved",
        "target_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf",
        "target_source_page": 34,
        "result_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf",
        "result_source_page": 42
      }
    ],
    "document_alignment_terms": {
      "must_support": [
        "The primary policy objectives of the National Blood Agreement signed by the Commonwealth, state and territory governments are:\n\nS to provide an adequate, safe, secure and affordabl",
        "To save and improve Australian lives and patient outcomes through a world-class blood supply. [AR p.16]"
      ],
      "watch_terms": [
        "National Supply Plan and Budget",
        "Appropriate access and use of immunoglobulin",
        "National performance reporting and benchmarking"
      ],
      "avoid_claiming_without_evidence": []
    },
    "review_note": "This entity appears to share a parent or related entity's strategy text; verify its own strategy before publishing."
  },
  "global_initiatives": null,
  "strategy": {
    "reporting_period": "2024-25",
    "corporate_plan_period": "2025-26",
    "vision": "To save and improve Australian lives and patient outcomes through a world-class blood supply. [AR p.16]",
    "vision_source_page": 16,
    "purposes": "The primary policy objectives of the National Blood Agreement signed by the Commonwealth, state and territory governments are:\n\nS to provide an adequate, safe, secure and affordable supply of blood products, blood related products and blood related services\nS to promote the safe and high-quality management and use of blood products, blood related products and blood related services in Australia. [CP p.10]",
    "purposes_source_page": 10,
    "how_we_deliver": "The NBA manages and coordinates arrangements for the supply of blood, blood products and blood services on behalf of all Australian governments in accordance with the National Blood Agreement. [CP p.10]",
    "how_we_deliver_source_page": 10,
    "government_priorities": [],
    "outcomes": [
      {
        "name": "Access to a secure supply of safe and affordable blood products",
        "description": "Access to a secure supply of safe and affordable blood products, including through national supply arrangements and coordination of best-practice standards within agreed funding policies under the national blood arrangements. [AR p.16]",
        "key_activities": [
          "works with all Australian governments to determine the clinical requirements for blood and blood-related products",
          "negotiates and manages national contracts with suppliers of blood and blood products",
          "assesses risks to the blood supply and develops contingency plans",
          "supports the work of all Australian governments to improve the way blood products are governed, managed and used"
        ],
        "source_page": 16
      }
    ],
    "values": [
      "APS Values"
    ],
    "values_framework_name": "APS Values",
    "kpi_targets_2025_26": [
      {
        "code": "NSP&B",
        "measure": "National Supply Plan and Budget",
        "target": "<5% variation",
        "source_page": 34
      },
      {
        "code": "Ig",
        "measure": "Appropriate access and use of immunoglobulin",
        "target": "<8% growth in Ig demand under approved criteria",
        "source_page": 34
      },
      {
        "code": "NBA",
        "measure": "National performance reporting and benchmarking",
        "target": "Published performance reporting and benchmarking information on the NBA website for the blood sector community",
        "source_page": 34
      }
    ],
    "kpi_results_2024_25": [
      {
        "code": "NSP&B",
        "measure": "National Supply Plan and Budget",
        "result": "Actual results were 4.3% ($79.4 million) below the National Supply Plan and Budget.",
        "status": "Not achieved",
        "source_page": 42
      },
      {
        "code": "Ig",
        "measure": "Appropriate access and use of immunoglobulin",
        "result": "The rate of growth of immunoglobulin (Ig) use was 6.7%.",
        "status": "Substantially achieved",
        "source_page": 42
      },
      {
        "code": "NBA",
        "measure": "National performance reporting and benchmarking",
        "result": "Published performance reporting and benchmarking information on the NBA website for the blood sector community.",
        "status": "Achieved",
        "source_page": 42
      }
    ],
    "_source_urls": {
      "annual_report_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf",
      "corporate_plan_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf"
    }
  },
  "ideas": [
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Data & Performance",
      "scale": "small",
      "title": "KPI evidence register with named owners",
      "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.",
      "quote": "[Page 63]\nPart 2: Annual performance 57\nTABLE 2.8 Supplier performance 2023–24: imported plasma and recombinant products\nPerformance measure KPI1 KPI2 KPI3 KPI4\nIn-country Shelf life on Reporting\nDelivery\nSupplier reserve product products accuracy and\nperformance\ninventory delivered timeliness\nSanofi-Aventis Australia Achieved Achieved Achieved Achieved\nPty Ltd (Alprolix, Eloctate)\nRoche Products Pty Ltd Achieved Achieved Achieved Achieved\n(Hemlibra)\nCSL Behring (Rhophylac, Achieved Achieved Achieved Achieved\nRiaSTAP, Fibrogammin,\nBerinert)\nCSL Behring (Factor XI Achieved Achieved Achieved Achieved\nConcentrate)\nNovo Nordisk Achieved Achieved Achieved Achieved\nPharmaceuticals Pty\nLtd (NovoSeven, Novo\nThirteen)\nPfizer Australia Pty Ltd Achieved Achieved Achieved Achieved\n(Xyntha, BeneFIX)\nTakeda Pharmaceuticals Achieved Achieved Achieved Achieved\nAustralia Pty Ltd (FEIBA,\nCeprotin)",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "annual-reports/2023-24.pdf (https://www.blood.gov.au/sites/default/files/documents/2024-10/NBA0912%20%E2%80%93%20NBA%20Annual%20Report%202023%E2%80%9324%20WCAG%20accessible.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Data & Performance",
      "scale": "large",
      "title": "Outcome dashboard linking budget, delivery, and public impact",
      "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.",
      "quote": "[Page 63]\nPart 2: Annual performance 57\nTABLE 2.8 Supplier performance 2023–24: imported plasma and recombinant products\nPerformance measure KPI1 KPI2 KPI3 KPI4\nIn-country Shelf life on Reporting\nDelivery\nSupplier reserve product products accuracy and\nperformance\ninventory delivered timeliness\nSanofi-Aventis Australia Achieved Achieved Achieved Achieved\nPty Ltd (Alprolix, Eloctate)\nRoche Products Pty Ltd Achieved Achieved Achieved Achieved\n(Hemlibra)\nCSL Behring (Rhophylac, Achieved Achieved Achieved Achieved\nRiaSTAP, Fibrogammin,\nBerinert)\nCSL Behring (Factor XI Achieved Achieved Achieved Achieved\nConcentrate)\nNovo Nordisk Achieved Achieved Achieved Achieved\nPharmaceuticals Pty\nLtd (NovoSeven, Novo\nThirteen)\nPfizer Australia Pty Ltd Achieved Achieved Achieved Achieved\n(Xyntha, BeneFIX)\nTakeda Pharmaceuticals Achieved Achieved Achieved Achieved\nAustralia Pty Ltd (FEIBA,\nCeprotin)",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "annual-reports/2023-24.pdf (https://www.blood.gov.au/sites/default/files/documents/2024-10/NBA0912%20%E2%80%93%20NBA%20Annual%20Report%202023%E2%80%9324%20WCAG%20accessible.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Risk & Assurance",
      "scale": "small",
      "title": "Recommendation tracker for audits, reviews, and inquiries",
      "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.",
      "quote": "In 2024–25, matters considered by the\nARC included:\nS financial reporting\nS engagement with NBA management and the ANAO in relation to the annual financial\nstatements audit, including formal clearance of annual financial statements\nS review of financial outcomes and budgets\nS performance reporting\nS Corporate Plan, Business Plan and Operational Scorecard\nS annual performance KPIs and reporting\nS systems of risk oversight and management\nS consideration of corporate issues and emerging risks affecting the organisation\nS fraud and risk management\nS reviewed accounting policies and frameworks\nS annual legislative compliance statement\nS risk roadmap and governance overview of blood supply\nS overview of IT security arrangements\nS systems of internal control\nS annual internal audit work plan, reports and implementation of recommendations.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "annual-reports/2024-25.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Risk & Assurance",
      "scale": "large",
      "title": "Integrated assurance and lessons-learned system",
      "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.",
      "quote": "In 2024–25, matters considered by the\nARC included:\nS financial reporting\nS engagement with NBA management and the ANAO in relation to the annual financial\nstatements audit, including formal clearance of annual financial statements\nS review of financial outcomes and budgets\nS performance reporting\nS Corporate Plan, Business Plan and Operational Scorecard\nS annual performance KPIs and reporting\nS systems of risk oversight and management\nS consideration of corporate issues and emerging risks affecting the organisation\nS fraud and risk management\nS reviewed accounting policies and frameworks\nS annual legislative compliance statement\nS risk roadmap and governance overview of blood supply\nS overview of IT security arrangements\nS systems of internal control\nS annual internal audit work plan, reports and implementation of recommendations.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "annual-reports/2024-25.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Citizen Services",
      "scale": "small",
      "title": "Plain-language service pages and proactive status updates",
      "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.",
      "quote": "[Page 138]\nOFFICIAL\n#\nNATIONAL BLOOD AUTHORITY\nADMINISTERED SCHEDULE OF COMPEHENSIVE INCOME\nfor the year ended 30 June 2025\n2025\nNotes $’000\n2024\nNET COST OF SERVICES $’000\nExpenses\n3,498\n1,753,189\nEmployee benefits 2.1A 294 2,237\nSuppliers - E 2.1B 628 1,669,757\nTotaGlr eanxptse -n nsoens -profit organisations 2.1C 1,757,609 344\nDepreciation and amortisation 4.2A 1,327\n1,673,665\nIncome\nRevenue\nNon-taxation revenue\n1,842,575\n6,598\nRevenue from contracts with customers 2.2A - 1,668,829\nTota In l t n e o re n s - t t a in x c a o t m io e n revenue 1,849,173 5,776\nOther revenue -\nTotal revenue 1,849,173\n1,674,605\nTotal income 1,849,173\n1,674,605\nNet contribution by services 91,564\n(Deficit)/Surplus 91,564 1,674,605\n940\nOTHER COMPREHENSIVE INCOME 940\nItems not subject to subsequent reclassification to net cost of services\nTotal comprehensive (loss)/income 91,564",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / service users",
      "source": "annual-reports/2024-25.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Citizen Services",
      "scale": "large",
      "title": "Single front door for life-event based services",
      "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.",
      "quote": "[Page 138]\nOFFICIAL\n#\nNATIONAL BLOOD AUTHORITY\nADMINISTERED SCHEDULE OF COMPEHENSIVE INCOME\nfor the year ended 30 June 2025\n2025\nNotes $’000\n2024\nNET COST OF SERVICES $’000\nExpenses\n3,498\n1,753,189\nEmployee benefits 2.1A 294 2,237\nSuppliers - E 2.1B 628 1,669,757\nTotaGlr eanxptse -n nsoens -profit organisations 2.1C 1,757,609 344\nDepreciation and amortisation 4.2A 1,327\n1,673,665\nIncome\nRevenue\nNon-taxation revenue\n1,842,575\n6,598\nRevenue from contracts with customers 2.2A - 1,668,829\nTota In l t n e o re n s - t t a in x c a o t m io e n revenue 1,849,173 5,776\nOther revenue -\nTotal revenue 1,849,173\n1,674,605\nTotal income 1,849,173\n1,674,605\nNet contribution by services 91,564\n(Deficit)/Surplus 91,564 1,674,605\n940\nOTHER COMPREHENSIVE INCOME 940\nItems not subject to subsequent reclassification to net cost of services\nTotal comprehensive (loss)/income 91,564",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / service users",
      "source": "annual-reports/2024-25.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Staff Productivity",
      "scale": "small",
      "title": "Reusable briefing and summary assistant for internal documents",
      "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.",
      "quote": "[Page 140]\nOFFICIAL\n#\nNATIONAL BLOOD AUTHORITY\nADMINISTERED RECONCILIATION SCHEDULE\nas at 30 June 2025\n2025\n$’000\n2024\n$’000\nOpening administered assets less administered liabilities as at 1 July 2024 417 085\n410,132\nNet (cost of) / contribution by services\n1,849,173\nIncome (1,757,609) 1,674,605\nExpenses\nPayments to entities other than corporate Commonwealth entities (1,673,665)\nOther comprehensive income\n64\nRevaluations transferred to reserves -\nTransfers (to) / from the Australian Government:\n8,429\nCloAsipnpgr aospsreiattsi olens tsr alinasbfielritsi ferso ams Oatff 3ic0ia Jlu Pnueb l2ic0 A25ccount: 517,142\nAnnual appropriations 6,013\nAccounting Policy 417,085\nAdministered cash transfers to and from the Official Public Account\nRevenue collected by the entity for use by the Government rather than the entity is administered revenue.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "annual-reports/2024-25.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Staff Productivity",
      "scale": "large",
      "title": "Department-wide knowledge and briefing platform",
      "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.",
      "quote": "[Page 140]\nOFFICIAL\n#\nNATIONAL BLOOD AUTHORITY\nADMINISTERED RECONCILIATION SCHEDULE\nas at 30 June 2025\n2025\n$’000\n2024\n$’000\nOpening administered assets less administered liabilities as at 1 July 2024 417 085\n410,132\nNet (cost of) / contribution by services\n1,849,173\nIncome (1,757,609) 1,674,605\nExpenses\nPayments to entities other than corporate Commonwealth entities (1,673,665)\nOther comprehensive income\n64\nRevaluations transferred to reserves -\nTransfers (to) / from the Australian Government:\n8,429\nCloAsipnpgr aospsreiattsi olens tsr alinasbfielritsi ferso ams Oatff 3ic0ia Jlu Pnueb l2ic0 A25ccount: 517,142\nAnnual appropriations 6,013\nAccounting Policy 417,085\nAdministered cash transfers to and from the Official Public Account\nRevenue collected by the entity for use by the Government rather than the entity is administered revenue.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "annual-reports/2024-25.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Regulation & Policy",
      "scale": "small",
      "title": "Regulatory burden scan for forms, guidance, and reporting",
      "idea": "Identify the top 10 highest-friction reporting obligations and simplify guidance, forms, or evidence requirements.",
      "quote": "Legislative and Policy Environment\n• National Blood Authority Act • National Blood Agreement • Domestic Supply Policy\n• Public Governance, (for the Australian Blood Sector) • Onshore Fractionation Policy\nPerformance and • Ministers’ Stewardship • Overseas Supply Policy\nAccountability Act Statement (for health providers)\n• NBA Corporate Plan\n• Public Service Act • Ministers’ Statement of\n• Auditor General Act Expectations (for Lifeblood)\nObjectives\n1 2 3\nSecure the supply of blood Improve risk management and Promote the safe and efficient\nand blood products blood sector performance use of blood and blood products\nHorizon-scanning\nStrategies\n• Provide a safe, secure affordable supply of • Promote a best practice model of the\nblood and blood related products and services management and use of blood and\n• Drive performance improvements in the blood-related products and services",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "corporate-plans/2025-26.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Regulation & Policy",
      "scale": "large",
      "title": "Adaptive regulation program with live feedback loops",
      "idea": "Create an adaptive regulation model using sandboxes, industry data, risk scoring, and regular rule updates.",
      "quote": "Legislative and Policy Environment\n• National Blood Authority Act • National Blood Agreement • Domestic Supply Policy\n• Public Governance, (for the Australian Blood Sector) • Onshore Fractionation Policy\nPerformance and • Ministers’ Stewardship • Overseas Supply Policy\nAccountability Act Statement (for health providers)\n• NBA Corporate Plan\n• Public Service Act • Ministers’ Statement of\n• Auditor General Act Expectations (for Lifeblood)\nObjectives\n1 2 3\nSecure the supply of blood Improve risk management and Promote the safe and efficient\nand blood products blood sector performance use of blood and blood products\nHorizon-scanning\nStrategies\n• Provide a safe, secure affordable supply of • Promote a best practice model of the\nblood and blood related products and services management and use of blood and\n• Drive performance improvements in the blood-related products and services",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "corporate-plans/2025-26.pdf (https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Procurement & Delivery",
      "scale": "small",
      "title": "Procurement lessons library for repeat purchases",
      "idea": "Capture reusable procurement clauses, market lessons, supplier performance notes, and common evaluation criteria.",
      "quote": "2023–24 highlights\nContracts\nThe NBA has transitioned from managing 5 supply contracts in 2003–04 to overseeing 18\ncontracts in 2023–24.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Delivery teams / suppliers",
      "source": "annual-reports/2023-24.pdf (https://www.blood.gov.au/sites/default/files/documents/2024-10/NBA0912%20%E2%80%93%20NBA%20Annual%20Report%202023%E2%80%9324%20WCAG%20accessible.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "category": "Procurement & Delivery",
      "scale": "large",
      "title": "Portfolio delivery office for major investments",
      "idea": "Stand up a portfolio delivery office that tracks benefits, risks, dependencies, procurement, and delivery confidence.",
      "quote": "2023–24 highlights\nContracts\nThe NBA has transitioned from managing 5 supply contracts in 2003–04 to overseeing 18\ncontracts in 2023–24.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Delivery teams / suppliers",
      "source": "annual-reports/2023-24.pdf (https://www.blood.gov.au/sites/default/files/documents/2024-10/NBA0912%20%E2%80%93%20NBA%20Annual%20Report%202023%E2%80%9324%20WCAG%20accessible.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    }
  ],
  "legislation_administered": [],
  "artifacts": [
    {
      "category": "annual-reports",
      "year": "2024-25",
      "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf",
      "file": "annual-reports/2024-25.pdf",
      "bytes": 3522745,
      "link_text": "NBA Annual Report 2024-25"
    },
    {
      "category": "annual-reports",
      "year": "2023-24",
      "url": "https://www.blood.gov.au/sites/default/files/documents/2024-10/NBA0912%20%E2%80%93%20NBA%20Annual%20Report%202023%E2%80%9324%20WCAG%20accessible.pdf",
      "file": "annual-reports/2023-24.pdf",
      "bytes": 5617686,
      "link_text": "NBA Annual Report 2023–24 (WCAG accessible)"
    },
    {
      "category": "corporate-plans",
      "year": "2025-26",
      "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf",
      "file": "corporate-plans/2025-26.pdf",
      "bytes": 6435684,
      "link_text": "NBA Corporate Plan 2025-26"
    }
  ],
  "_meta": {
    "snapshot_built_at": "2026-05-14T02:12:13+00:00",
    "strategy_brief_meta": {
      "model": "nova-micro",
      "folder": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "annual_report": {
        "file": "annual-reports\\2024-25.txt",
        "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf",
        "year": "2024-25"
      },
      "corporate_plan": {
        "file": "corporate-plans\\2025-26.txt",
        "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf",
        "year": "2025-26"
      },
      "usage": {
        "input_tokens": 37457,
        "output_tokens": 824,
        "total_tokens": 38281,
        "model": "nova-micro"
      },
      "cost_usd": 0.0014263550000000002,
      "elapsed_seconds": 5.92,
      "generated_at": "2026-05-13T03:57:18+00:00"
    },
    "ideas_manifest": {
      "entity_id": "B-002550",
      "entity_name": "Australian Bleeding Disorders Registry Steering Committee",
      "folder_name": "Australian-Bleeding-Disorders-Registry-Steering-Committee",
      "generated_at": "2026-05-09T23:05:41.774023+00:00",
      "idea_count": 12,
      "markdown": "ideas/Australian-Bleeding-Disorders-Registry-Steering-Committee_ideas.md",
      "jsonl": "ideas/ideas.jsonl",
      "inputs": [
        "Australian-Bleeding-Disorders-Registry-Steering-Committee_strategy-overview.md",
        "strategy-evidence.json",
        "global-intelligence/source-manifest.json"
      ]
    },
    "global_intel_meta": null
  }
}